{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T00:02:50Z","timestamp":1756425770591,"version":"3.44.0"},"reference-count":13,"publisher":"BMJ","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Case Reports"],"accepted":{"date-parts":[[2017,4,2]]},"abstract":"<jats:p>Vaso-occlusive crises are the most common manifestation of sickle cell disease (SCD) and the main cause of hospital admission in these patients. There is emerging evidence that vaso-occlusive pain has both nociceptive and neuropathic components. However, the treatment of SCD-related pain with neuropathic drugs has not yet been systematically studied, particularly in children. We describe a 14-year-old girl with SCD and multiple hospital admissions for pain management for severe acute vaso-occlusive pain episodes. The patient was evaluated by a multidisciplinary team of specialists which considered that the chronic, refractory pain she was experiencing for years was probably neuropathic in origin and it was decided to start oral gabapentin (300\u2009mg\/day). At 10 months follow-up, the patient reported remarkable improvement in her quality of life with a significant decrease in the number of hospital admissions (three admissions for acute vaso-occlusive pain episodes in 10 months versus the previously monthly recurrences).<\/jats:p>","DOI":"10.1136\/bcr-2016-218614","type":"journal-article","created":{"date-parts":[[2017,4,21]],"date-time":"2017-04-21T08:22:30Z","timestamp":1492762950000},"page":"bcr-2016-218614","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":3,"title":["Use of gabapentin in the treatment of chronic pain in an adolescent with sickle cell disease"],"prefix":"10.1136","volume":"2017","author":[{"given":"C\u00e1tia R","family":"Correia","sequence":"first","affiliation":[{"name":"Pediatrics, Hospital de S\u00e3o Francisco Xavier, Centro Hospitalar de Lisboa Ocidental, Lisboa, Portugal"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana Teresa","family":"Soares","sequence":"additional","affiliation":[{"name":"Pediatrics, Hospital Garcia de Orta, Almada, Portugal"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Azurara","sequence":"additional","affiliation":[{"name":"Pediatrics, Hospital de S\u00e3o Francisco Xavier, Centro Hospitalar de Lisboa Ocidental, Lisboa, Portugal"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Jo\u00e3o","family":"Palar\u00e9","sequence":"additional","affiliation":[{"name":"Pediatrics, Hospital Santa Maria, Lisboa, Portugal"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2017,4,21]]},"reference":[{"key":"2025082800330406000_2017.apr21_1.bcr-2016-218614.1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.20944"},{"key":"2025082800330406000_2017.apr21_1.bcr-2016-218614.2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2003.04193.x"},{"key":"2025082800330406000_2017.apr21_1.bcr-2016-218614.3","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1097\/MPH.0000000000000265","article-title":"The use of neuropathic pain drugs in children with sickle cell disease is associated with older age, female sex, and longer length of hospital stay","volume":"37","author":"Brandow","year":"2015","journal-title":"J Pediatr Hematol Oncol"},{"key":"2025082800330406000_2017.apr21_1.bcr-2016-218614.4","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2010.1.409"},{"key":"2025082800330406000_2017.apr21_1.bcr-2016-218614.5","doi-asserted-by":"publisher","DOI":"10.1177\/1740774516636573"},{"key":"2025082800330406000_2017.apr21_1.bcr-2016-218614.6","doi-asserted-by":"publisher","DOI":"10.1016\/j.hoc.2005.07.008"},{"key":"2025082800330406000_2017.apr21_1.bcr-2016-218614.7","first-page":"33","article-title":"The mechanism of action of gabapentin in neuropathic pain","volume":"7","author":"Baillie","year":"2006","journal-title":"Curr Opin Investig Drugs"},{"key":"2025082800330406000_2017.apr21_1.bcr-2016-218614.8","doi-asserted-by":"publisher","DOI":"10.1111\/j.1460-9592.2005.01687.x"},{"key":"2025082800330406000_2017.apr21_1.bcr-2016-218614.9","doi-asserted-by":"publisher","DOI":"10.1016\/S0887-8994(99)00139-3"},{"key":"2025082800330406000_2017.apr21_1.bcr-2016-218614.10","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.24838"},{"key":"2025082800330406000_2017.apr21_1.bcr-2016-218614.11","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-04-383430"},{"key":"2025082800330406000_2017.apr21_1.bcr-2016-218614.12","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-12-327429"},{"key":"2025082800330406000_2017.apr21_1.bcr-2016-218614.13","first-page":"533","article-title":"Depression in sickle cell disease","volume":"95","author":"Hasan","year":"2003","journal-title":"J Natl Med Assoc"}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2016-218614","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T07:33:13Z","timestamp":1756366393000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2016-218614"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4,21]]},"references-count":13,"alternative-id":["10.1136\/bcr-2016-218614"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2016-218614","relation":{},"ISSN":["1757-790X"],"issn-type":[{"type":"electronic","value":"1757-790X"}],"subject":[],"published":{"date-parts":[[2017,4,21]]}}}